Telik, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs to treat cancer. The company’s lead drug product candidate in clinical development includes TELINTRA, a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1, which is under Phase II clinical trial for the treatment of blood disorders associated with low blood cell levels, such as anemia, neutropenia, or thrombocytopenia. Its preclinical drug product developments include TLK60404, a small molecule compound, which inhibits Aurora kinase and VEGFR kinase; TLK60357, a novel, small molecule inhibitor of cell division that inhibits the formation of microtubules necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death; and TLK60596, a VGFR kinase inhibitor that blocks the formation of new blood vessels in tumors. The company’s product candidates are discovered using its proprietary technology, target-related affinity profiling (TRAP), which enables the discovery of small molecule product candidates. Telik, Inc. was founded in 1988 and is based in Palo Alto, California.

Key Statistics